Patent ID: 11904081
Assignee: LUPAGEN, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A

Claim 1:
2. The system of claim 1, wherein the cell customization module comprises:
(a) a temperature control unit capable of reaching and maintaining temperatures within the unit of between 0° C. and 37° C., inclusive; a cell washing unit comprising a chamber that mixes target nucleated blood cells with at least one wash solution that dilutes or removes a plasma component from the target nucleated blood cells and places washed cells into suspension prior to their modification; an inlet for introducing a nucleic acid preparation to the suspension of washed cells, or a chamber comprising a nucleic acid preparation into which a washed cell suspension is introduced; and an electroporation chamber, connected to a power source effective to electroporate the nucleic acid into a target nucleated blood cell, wherein temperature control unit, the cell washing unit, and the electroporation chamber are positioned in the temperature control unit;
(b) a temperature control unit capable of reaching and maintaining temperatures between 4° C. and 37° C., inclusive; a cell-washing unit comprising a chamber that mixes target nucleated blood cells with at least one wash solution that dilutes or removes a plasma component from the target nucleated blood cells and places washed cells into suspension prior to their modification; and an inlet for introducing a nucleic acid preparation to the suspension of washed cells, or a chamber comprising a nucleic acid preparation into which a washed cell suspension is introduced, the nucleic acid preparation comprising a lipid transfection reagent;
(c) a chamber in fluid communication with and configured to receive a suspension of enriched target nucleated blood cells from the cell separation module, the chamber comprising an inlet for the introduction of a modifying agent or comprising a preparation of modifying agent, and a plurality of microfluidic channels that narrow over their length to at least 20-99% of the diameter of the enriched target nucleated blood cells; and a source of pressure sufficient to squeeze suspended cells through the plurality of microfluidic channels in the presence of the modifying agent;
(d) a temperature control unit capable of reaching and maintaining temperatures between 4° C. and 37° C., inclusive; a cell-washing unit comprising a chamber that mixes target nucleated blood cells with at least one wash solution that dilutes or removes a plasma component from the target nucleated blood cells and places washed cells into suspension prior to their modification; and an inlet for introducing one or more modifying agents to the suspension of washed cells, or a chamber comprising one or more modifying agents into which a washed cell suspension is introduced, thereby allowing contacting of the washed cells with the one or more modifying agents; or
(e) a temperature control unit capable of reaching and maintaining temperatures between 4° C. and 37° C., inclusive; a cell-washing unit comprising a chamber that mixes target nucleated blood cells with at least one wash solution that dilutes or removes a plasma component from the target nucleated blood cells and places washed cells into suspension prior to their modification; and an inlet for introducing one or more modifying agents in a membrane disruptive delivery solution to the suspension of washed cells, or a chamber comprising one or more modifying agents in a membrane disruptive delivery solution into which a washed cell suspension is introduced thereby allowing contacting of the washed cells with the one or more modifying agents in the membrane disruptive solution.